Literature DB >> 11122800

Salvage therapy for ovarian cancer.

A A Garcia1.   

Abstract

The majority of patients with ovarian cancer will relapse after initial chemotherapy and will be candidates for salvage treatment. Currently, five agents show clear activity in patients with platinum- and paclitaxel-resistant disease: topotecan, oral etoposide, liposomal doxorubicin, gemcitabine, and, possibly, docetaxel. In addition, other agents have activity in platinum-resistant patients: vinorelbine, tamoxifen, ifosfamide, altretamine, 5-fluorouracil with leucovorin, and, possibly, irinotecan. Furthermore, selected patients may benefit from other therapeutic approaches such as surgery or radiation therapy.

Entities:  

Mesh：

Year:  1999        PMID： 11122800     DOI： 10.1007/s11912-999-0012-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  58 in total

1.  Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.

Authors:  P Chollet; M A Bensmaïne; S Brienza; C Deloche; H Curé; H Caillet; E Cvitkovic
Journal:  Ann Oncol       Date:  1996-12       Impact factor: 32.976

2.  Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

Authors:  J D Shapiro; M J Millward; D Rischin; M Michael; V Walcher; P A Francis; G C Toner
Journal:  Gynecol Oncol       Date:  1996-10       Impact factor: 5.482

3.  Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

Authors:  G J Creemers; C J Gerrits; J R Eckardt; J H Schellens; H A Burris; A S Planting; G I Rodriguez; W J Loos; I Hudson; C Broom; J Verweij; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

4.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

5.  Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

Authors:  G J Creemers; G Bolis; M Gore; G Scarfone; A J Lacave; J P Guastalla; R Despax; G Favalli; R Kreinberg; S Van Belle; I Hudson; J Verweij; W W Ten Bokkel Huinink
Journal:  J Clin Oncol       Date:  1996-12       Impact factor: 44.544

6.  Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.

Authors:  P Hoskins; E Eisenhauer; S Beare; M Roy; P Drouin; G Stuart; P Bryson; R Grimshaw; V Capstick; B Zee
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

7.  Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer.

Authors:  P Jong; J Sturgeon; C G Jamieson
Journal:  Can J Surg       Date:  1995-10       Impact factor: 2.089

8.  Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.

Authors:  R de Wit; M E van der Burg; A van den Gaast; A Logmans; G Stoter; J Verweij
Journal:  Ann Oncol       Date:  1994-09       Impact factor: 32.976

Review 9.  Oxaliplatin: a review of preclinical and clinical studies.

Authors:  E Raymond; S G Chaney; A Taamma; E Cvitkovic
Journal:  Ann Oncol       Date:  1998-10       Impact factor: 32.976

10.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

Authors:  E L Trimble; J D Adams; D Vena; M J Hawkins; M A Friedman; J S Fisherman; M C Christian; R Canetta; N Onetto; R Hayn
Journal:  J Clin Oncol       Date:  1993-12       Impact factor: 44.544
View more
  1 in total

1.  Salvage therapy with topotecan in heavily pretreated ovarian cancer patients.

Authors:  Lubomir Bodnar; Gabriel Wcislo; Anna Nasilowska; Katarzyna Szarlej-Wcislo; Agnieszka Gasowska-Bodnar; Marta Smoter; Cezary Szczylik
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-26       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.